1. New Options for the Treatment of Hepatocellular Carcinoma

2. Incidence and Impact of HCC

3. Today's Program: A Focus on Unresectable Disease

4. Patient Case #1: Front-Line

5. SHARP Trial: Front-Line Sorafenib Efficacy

6. SHARP Trial: AEs

7. Lenvatinib vs Sorafenib Efficacy: REFLECT

8. Lenvatinib Is Non-Inferior to Sorafenib in First-Line Advanced HCC

9. Lenvatinib vs Sorafenib: AEs

10. Patient Case #1 (cont)

11. Pharmacist's Role in Maintaining Compliance With Oral Medications

12. Managing AEs: Diarrhea

13. Lenvatinib Dosing Considerations

14. Patient Case #1 Conclusion

15. Patient Case #2

16. CELESTIAL Trial: Cabozantinib

17. Cabozantinib Toxicity Consistent With Other TKIs

18. REACH Trials: Ramucirumab

19. AEs With Ramucirumab

20. CheckMate 040 Trial: Nivolumab

21. CheckMate 040 Trial: AEs

22. KEYNOTE-224 Trial: Pembrolizumab

23. Considerations for Second-Line Treatment Selection

24. Selecting Optimal Second-Line Treatment

25. Patient Case #2 (cont)

26. Managing irAEs: Rash

27. Patient Case #2 Conclusion

28. Concluding Remarks

29. Abbreviations

30. Abbreviations (cont)